round button
Leave a message

全球第三代心室辅助装置市场——行业趋势及 2030 年预测

请求目录 请求目录 与分析师交谈 与分析师交谈 立即购买 立即购买 购买前请咨询 提前咨询 免费样本报告 免费样本报告

全球第三代心室辅助装置市场——行业趋势及 2030 年预测

  • Medical Devices
  • Upcoming Report
  • Nov 2022
  • Global
  • 350 页面
  • 桌子數: 220
  • 图号: 60

Global Third Generation Ventricular Assist Devices Market

市场规模(十亿美元)

CAGR :  % Diagram

Chart Image USD 2.50 Billion USD 9.08 Billion 2023 2030
Diagram Forecast Period
2023 –2030
Diagram Market Size (Base Year)
USD 2.50 Billion
Diagram Market Size (Forecast Year)
USD 9.08 Billion
Diagram CAGR
%
Diagram Major Markets Players
  • Dummy1
  • Dummy2
  • Dummy3
  • Dummy4
  • Dummy5

全球第三代心室辅助装置市场,按产品(左心室辅助装置 (LVAD)、右心室辅助装置 (RVAD)、双心室辅助装置 (BIVAD)、经皮心室辅助装置 (PVAD)、全人工心脏 (TAH))、应用(目的疗法、桥接候选 (BTC) 疗法、桥接移植 (BTT) 疗法、桥接康复 (BTR) 疗法、其他)、年龄(18 岁以下、19-39 岁、40-59 岁、60-79 岁、80 岁以上)、流量(脉动流、连续流)、设计(经皮、植入式)、技术(磁力、流体动力悬浮)– 行业趋势和预测到 2030 年。

第三代心室辅助装置市场

 第三代心室辅助装置市场分析及规模

根据世界卫生组织 2021 年的数据,全球每年约有 1790 万人死于心血管疾病。这占全球所有死亡人数的 35%。此外,心脏病发作和中风占所有心血管疾病死亡人数的 85%。根据 Cureus Journal of Medical Science 2020 年 7 月发表的一篇文章,缺血性心脏病(IHD) 是全球死亡的主要原因。缺血性心脏病影响约 1.26 亿人(每 100,000 人中有 1,655 人),约占世界人口的 1.72%。到 2030 年,全球缺血性心脏病的患病率预计将超过每 100,000 人中有 1,845 人。

Data Bridge Market Research 分析,第三代心室辅助装置市场在 2022 年为 25 亿美元,预计到 2030 年将达到 90.8 亿美元,在 2023 年至 2030 年的预测期内复合年增长率为 17.50%。除了对市场价值、增长率、细分、地理覆盖范围和主要参与者等市场情景的见解外,Data Bridge Market Research 策划的市场报告还包括深度专家分析、患者流行病学、管道分析、定价分析和监管框架。

第三代心室辅助装置的市场范围和细分      

报告指标

细节

预测期

2023 至 2030 年

基准年

2022

历史岁月

2021(可定制为 2015 - 2020)

定量单位

收入(单位:十亿美元)、销量(单位:台)、定价(美元)

涵盖的领域

产品(左心室辅助装置 (LVAD)、右心室辅助装置 (RVAD)、双心室辅助装置 (BIVAD)、经皮心室辅助装置 (PVAD)、全人工心脏 (TAH))、应用(目标疗法、过渡至候选 (BTC) 疗法、过渡至移植 (BTT) 疗法、过渡至康复 (BTR) 疗法、其他)、年龄(18 岁以下、19-39 岁、40-59 岁、60-79 岁、80 岁以上)、流量(脉动流、连续流)、设计(经皮、植入式)、技术(磁悬浮、流体动力悬浮)

覆盖国家

U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America

Market Players Covered

ABIOMED (U.S.), Asahi Kasei Corporation (Japan), Abbott (U.S.), Calon Cardio (U.K.), Jarvik Heart, Inc. (U.S.), Medtronic (Ireland), Terumo Corporation (Japan), BiVACOR Inc. (U.S.), Cardiobridge GmbH (Germany), CHF Solutions, Inc. (U.S.), Evaheart, Inc. (U.S.), LivaNova PLC (U.K.), CorWave SA (France), Fresenius Medical Care AG & Co. KGaA (Germany), MiTiHeart Corporation (U.S.), Getinge AB (Sweden), SynCardia Systems, LLC (U.S.), Teleflex Incorporated (U.S.), Mayo Foundation for Medical Education and Research (MFMER) (U.S.)

Market Opportunities

  • Rising prevalence of chronic disorders like diabetes, neurological disorders

Market Definition

Third-generation ventricular assist devices (VADs) are continuous-flow rotary pumps with a fully levitated impeller/rotor and no mechanical contact between the rotating and stationary parts of the pump in normal operation. Third-generation VADs have emerged with the promise of improved hemocompatibility and durability over second-generation devices. However, most third-generation devices have not demonstrated a significant advantage over their second-generation counterparts, frequently trading an improvement in one aspect of performance for a disadvantage in another.

Global Third Generation Ventricular Assist Devices Market Dynamics

Drivers

  • Technological advancements

The VAD market is constantly changing, with key players investing in product innovation and development. The market for VAD is expected to be driven by technological advancements combined with timely regulatory approvals in the form of small-size devices with features such as infection control. Berlin Heart announced in June 2020 that the US FDA's required Post Market Approval (PMA) for EXCOR Pediatric VAD was completed. Furthermore, benefits associated with the use of VADs include increased abidance, functionality, and durability, which increase product adoption and thus support market growth.

  • Rising private equity firms

Private equity firms and venture capitalists are making investments in the growing third generation VAD market to promote product development. For instance, CorWave raised USD 40.0 million in a Series C funding round led by three new and returning investors in January 2021 for its implantable heart pump based on a novel technology, the wave membrane pump, including Novo Holdings, Bpifrance, Sofinnova Partners, Seventure, Ysios Capital, European Commission, Singaporean family office M&L Healthcare, and Financière Arbevel.

Opportunities

  • Novel advancements

Advances in novel VADs for surgical interventions, particularly in paediatric patients suffering from cardiac disorders, are expected to increase the demand. For instance, the US Food and Drug Administration graded the continuous-flow LVADs, Micromed HeartAssist 5TM Pediatric VAD, and Berlin HeartTM EXCOR paediatric VAD for paediatric patients. Since 2011, Berlin HeartTM EXCOR has been approved for use as a bridge-to-transplantation device.

Increasing incidence of organ transplantation

The rising prevalence of cardiovascular diseases and growing risks of organ failures is supporting the growth in organ transplant demand. The shortage of organ donors delays the organ transplantation procedure. As per United Network for Organ Sharing, nearly 121,016 people need organ transplantation and approximately 77,725 people are on the active waiting list.

Restraints/Challenges

  • High costs

High costs associated with procedure and device usage, a lack of government reimbursement policies, and an increasing number of serious risks involved in procedure are acting as market restraints for the growth of third-generation ventricular assist devices during the forecast period. The most difficult challenge for market growth will be the increased development of affordable, small, and efficient devices.

This third generation ventricular assist devices market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the third generation ventricular assist devices market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.

COVID-19 Impact on the Third Generation Ventricular Assist Devices Market

The ongoing Covid-19 pandemic has had a negative impact on the third generation ventricular assist devices market, with the government imposing temporary lockdowns and travel restrictions, resulting in a decrease in the number of surgical procedures. For instance, the global revenue of the ABIOMED Impella heart pump was impacted in the fourth quarter of FY2020 due to lower patient utilization and the significant impact of the COVID-19 pandemic on surgeries, elective medical procedures, and fewer patients seeking treatment at hospitals.

Recent Developments

  • In June 2020, The FDA approved the company's First-in-Human Trial of Impella ECP, which will be studied in high-risk percutaneous coronary intervention patients. In addition, to strengthen their business and expand the reach of their device, they are implementing various strategies such as mergers and acquisitions and expanding their manufacturing facilities.

Global Third Generation Ventricular Assist Devices Market Scope

The third generation ventricular assist devices market is segmented on the basis of product, application, age, flow, design, and technology. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.

Product

  • Left Ventricular Assist Devices (LVADs)
  • Right Ventricular Assist Devices (RVADs)
  • Biventricular Assist Devices (BIVADs)
  • Percutaneous Ventricular Assist Devices (PVADs)
  • Total Artificial Heart (TAH)

 Application

  • Destination Therapy
  • Bridge-to-Candidacy (BTC) Therapy
  • Bridge-to-Transplant (BTT) Therapy
  • Bridge-to-Recovery (BTR) Therapy
  • Others

 Age

  • Below 18 Years
  • 19-39 Years
  • 40-59 Years
  • 60-79 Years
  • Above 80 Years

 Flow

  • Pulsatile Flow
  • Continuous Flow
  • Axial continuous flow
  • Centrifugal continuous flow

 Design

  • Transcutaneous
  • Implantable

 Technology

  • Magnetic
  • Hydrodynamic Levitation

Third Generation Ventricular Assist Devices Market Regional Analysis/Insights

The third generation ventricular assist devices market is analyzed and market size insights and trends are provided by country, product, application, age, flow, design, and technology as referenced above.

The countries covered in the third generation ventricular assist devices market report are U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.

由于公众健康意识的不断提高、完善的医疗政策的普及以及该地区心血管疾病的高发性,北美在第三代心室辅助装置市场占据主导地位。

由于“印度制造”等举措不断增加,以及该地区对医疗保健行业增长的投资水平不断飙升,预计亚太地区将在 2023 年至 2030 年的预测期内实现最高增长率。

报告的国家部分还提供了影响单个市场因素和国内市场监管变化,这些因素和变化会影响市场的当前和未来趋势。下游和上游价值链分析、技术趋势和波特五力分析、案例研究等数据点是用于预测单个国家市场情景的一些指标。此外,在提供国家数据的预测分析时,还考虑了全球品牌的存在和可用性以及它们因来自本地和国内品牌的激烈或稀缺竞争而面临的挑战、国内关税和贸易路线的影响。

医疗保健基础设施增长安装基础和新技术渗透

第三代心室辅助装置市场还为您提供了每个国家/地区资本设备医疗支出增长、第三代心室辅助装置市场不同类型产品的安装基数、使用生命线曲线的技术影响以及医疗监管情景的变化及其对第三代心室辅助装置市场的影响的详细市场分析。数据适用于 2011-20201 年的历史时期。

竞争格局和第三代心室辅助装置市场份额分析

第三代心室辅助装置市场竞争格局按竞争对手提供详细信息。详细信息包括公司概况、公司财务状况、收入、市场潜力、研发投资、新市场计划、全球影响力、生产基地和设施、生产能力、公司优势和劣势、产品发布、产品宽度和广度、应用主导地位。以上提供的数据点仅与公司对第三代心室辅助装置市场的关注有关。

第三代心室辅助装置市场的一些主要参与者包括:

  • ABIOMED(美国)
  • 旭化成株式会社(日本)
  • 雅培(美国)
  • Calon Cardio(英国)
  • Jarvik Heart, Inc.(美国)
  • 美敦力(爱尔兰)
  • 泰尔茂株式会社 (日本)
  • BiVACOR Inc.(美国)
  • Cardiobridge GmbH(德国)
  • CHF Solutions, Inc.(美国)
  • Evaheart, Inc.(美国)
  • LivaNova PLC(英国)
  • CorWave SA(法国)
  • 费森尤斯医疗保健股份公司(德国)
  • MiTiHeart Corporation(美国)
  • Getinge AB(瑞典)
  • SynCardia Systems, LLC(美国)
  • Teleflex Incorporated(美国)
  • 梅奥医学教育与研究基金会(MFMER)(美国)

研究方法:全球第三代心室辅助装置市场

数据收集和基准年分析是使用具有大样本量的数据收集模块进行的。市场数据使用市场统计和连贯模型进行分析和估计。市场份额分析和关键趋势分析也是市场报告中的主要成功因素。如需了解更多信息,请请求分析师致电或下拉询问。

DBMR 研究团队使用的关键研究方法是数据三角测量,涉及数据挖掘、数据变量对市场影响的分析以及主要(行业专家)验证。除此之外,数据模型还包括供应商定位网格、市场时间线分析、市场概览和指南、公司定位网格、公司市场份额分析、测量标准、全球与区域和供应商份额分析。要了解有关研究方法的更多信息,请向我们的行业专家咨询。

可定制

Data Bridge Market Research 是高级形成性研究领域的领导者。我们很自豪能够为现有和新客户提供符合其目标的数据和分析。报告可以定制,包括目标品牌的价格趋势分析、了解其他国家的市场(索取国家列表)、临床试验结果数据、文献综述、翻新市场和产品基础分析。目标竞争对手的市场分析可以从基于技术的分析到市场组合策略进行分析。我们可以按照您所需的格式和数据样式添加您需要的任意数量的竞争对手数据。我们的分析师团队还可以为您提供原始 Excel 文件数据透视表(Factbook)中的数据,或者可以帮助您根据报告中的数据集创建演示文稿。 


SKU-

Get online access to the report on the World's First Market Intelligence Cloud

  • Interactive Data Analysis Dashboard
  • Company Analysis Dashboard for high growth potential opportunities
  • Research Analyst Access for customization & queries
  • Competitor Analysis with Interactive dashboard
  • Latest News, Updates & Trend analysis
  • Harness the Power of Benchmark Analysis for Comprehensive Competitor Tracking
Request for Demo

研究方法

Data collection and base year analysis are done using data collection modules with large sample sizes. The stage includes obtaining market information or related data through various sources and strategies. It includes examining and planning all the data acquired from the past in advance. It likewise envelops the examination of information inconsistencies seen across different information sources. The market data is analysed and estimated using market statistical and coherent models. Also, market share analysis and key trend analysis are the major success factors in the market report. To know more, please request an analyst call or drop down your inquiry.

The key research methodology used by DBMR research team is data triangulation which involves data mining, analysis of the impact of data variables on the market and primary (industry expert) validation. Data models include Vendor Positioning Grid, Market Time Line Analysis, Market Overview and Guide, Company Positioning Grid, Patent Analysis, Pricing Analysis, Company Market Share Analysis, Standards of Measurement, Global versus Regional and Vendor Share Analysis. To know more about the research methodology, drop in an inquiry to speak to our industry experts.

可定制

Data Bridge Market Research is a leader in advanced formative research. We take pride in servicing our existing and new customers with data and analysis that match and suits their goal. The report can be customized to include price trend analysis of target brands understanding the market for additional countries (ask for the list of countries), clinical trial results data, literature review, refurbished market and product base analysis. Market analysis of target competitors can be analyzed from technology-based analysis to market portfolio strategies. We can add as many competitors that you require data about in the format and data style you are looking for. Our team of analysts can also provide you data in crude raw excel files pivot tables (Fact book) or can assist you in creating presentations from the data sets available in the report.

Frequently Asked Questions

The growth rate of the third generation ventricular assist devices market is 17.50%.
The third generation ventricular assist devices market size will be worth USD 9.08 billion by 2030.
Technological advancements & rising private equity firms are the growth drivers of the third generation ventricular assist devices market.
Product, application, age, flow, design, and technology are the factors on which the third generation ventricular assist devices market research is based.
Major companies in the third generation ventricular assist devices market are ABIOMED (U.S.), Asahi Kasei Corporation (Japan), Abbott (U.S.), Calon Cardio (U.K.), Jarvik Heart, Inc. (U.S.), Medtronic (Ireland), Terumo Corporation (Japan), BiVACOR Inc. (U.S.), Cardiobridge GmbH (Germany), CHF Solutions, Inc. (U.S.), Evaheart, Inc. (U.S.), LivaNova PLC (U.K.), CorWave SA (France), Fresenius Medical Care AG & Co. KGaA (Germany), MiTiHeart Corporation (U.S.), Getinge AB (Sweden), SynCardia Systems, LLC (U.S.), Teleflex Incorporated (U.S.), Mayo Foundation for Medical Education and Research (MFMER) (U.S.).
Testimonial
a